treatment

Bio & Pharma Celltrion wins EU approval for autoimmune disease treatment Avtozma

Celltrion Inc.’s Avtozma, a biosimilar to Roche’s autoimmune disease treatment Actemra, has won approval from the European Commission, f...

Corporate restructuring SK Ecoplant seeks to sell waste treatment business for $1.4 billion

SK Ecoplant Co., a South Korean construction engineering and waste management company under SK Group, is seeking to dispose of its waste treatment b...

Mergers & Acquisitions LG Chem embarks on sale of dermal filler business worth $343 million

LG Chem Ltd., the world’s fourth-largest chemicals producer that is fostering vaccine and new drug development as new growth drivers, has kick...

Bio & Pharma Celltrion’s Vegzelma: Most-prescribed cancer treatment in Europe

South Korea’s leading biosimilar drug developer Celltrion Inc.'s Vegzelma, a cancer drug referencing global biopharma Roche’s Avastin, h...

Bio & Pharma Yuhan’s lung cancer drug gets OK in Europe

Leclaza (ingredient: lazertinib), a new lung cancer treatment developed by South Korea’s Yuhan Corp. secured approval from the European Commis...

Bio & Pharma Celltrion obtains approval of Steqeyma from FDA

South Korea's Celltrion Inc. said on Wednesday it received new drug submission (NDS) approval from the Food and Drug Administration (FDA) for Steq...

Bio & Pharma SK Pharmteco bags obesity treatment deal worth up to $1.4 bn

SK Pharmteco Co., a contract development and manufacturing organization (CDMO), has secured an obesity treatment order worth up to 2 trillion won ($...

Bio & Pharma Celltrion gets approval of Omlyclo in Canada

South Korea’s Celltrion Inc., received new drug submission (NDS) approval from Health Canada for Omlyclo, the biosimilar of allergic asthma an...

Bio & Pharma Celltrion releases Steqeyma in Europe

South Korea's Celltrion Inc. said on Monday it released Steqeyma (ustekinumab) in Europe, the biosimilar of autoimmune disease treatment Stelara.T...

Energy DS Dansuk wins $750 mn SAF material order from Phillips 66

South Korea's DS Dansuk Co., which operates bioenergy, battery, and plastic recycling businesses, said on Monday it signed a 1 trillion won ($750 mi...

Bio & Pharma ViGenCell obtains approval for HLA-B5801 genetic diagnostic kit for adverse reactions to gout treatment

ViGenCell, a company specializing in immunotherapy, announced on Friday that it has obtained approval from the Ministry of Food and Drug Safety (MFD...

Bio & Pharma Celltrion's anti cancer drugs hold 90% market share in C.America

South Korea’s Celltrion Inc. said on Friday that its cancer treatments have captured a 90% market share in several Central American countries....

Bio & Pharma Osstem Implant to boost digital dentistry business

South Korea's Osstem Implant Co., the world’s fourth-largest dental implant maker, will enhance its software system of digital dentistry. ...

Bio & Pharma Celltrion to supply breast, stomach cancer treatment to Brazil

Celltrion Inc., South Korea’s largest biosimilar maker, announced on Friday that its breast and stomach cancer treatment "Herzuma" (active ing...

Bio & Pharma SK Group’s 3rd-generation daughter comes to the fore

Chey Yoon-chung, the eldest daughter of SK Group Chairman Chey Tae-won, unexpectedly made her debut during an SK Biopharmaceuticals Co. video confer...

Mergers & Acquisitions GS E&C in talks to sell entire stake in GS Elevator to Chinese firm

South Korea’s GS Engineering & Construction Corp. (GS E&C) is in talks to sell its entire stake in GS Elevator Co. to a Chinese strate...

Bio & Pharma Celltrion gets approval of Steqeyma in Canada

South Korea’s Celltrion Inc., received new drug submission (NDS) approval from Health Canada for Steqeyma, a biosimilar of the autoimmune dise...

Bio & Pharma GC Biopharma sells HK subsidiary to CR Pharm Group for $254 mn

South Korea’s GC Biopharma Corp. announced on Wednesday that it signed a share purchase agreement (SPA) to sell all its shares in its Hong Kon...

Bio & Pharma LG Chem launches Synovian in China

South Korea's LG Chem Ltd. announced on Wednesday that it launched its homegrown new drug for osteoarthritis Synovian (marketed in China as Hyruan O...

Bio & Pharma Handok gets Biocon's obesity drug exclusive distribution in S.Korea

South Korean pharmaceutical company Handok Inc. announced on Friday that it signed an exclusive domestic sales and distribution agreement with India...

Bio & Pharma Investors dump Korean biotech HLB stocks on FDA rejection

HLB Co. and its affiliate stocks tumbled on Friday on news that the South Korean biotech group’s highly anticipated new cancer treatment Rivoc...

Bio & Pharma Celltrion to supply Remsima, Herzuma to Peru

South Korea's Celltrion Inc. announced on Thursday that it secured a contract to supply its biosimilars for autoimmune disease treatment and antican...

Bio & Pharma Samsung Bioepis gets OK to sell Stelara biosimilar in Europe

South Korea's Samsung Bioepis has received approval from the European Commission to sell Pyzchiva, a biosimilar of the autoimmune disease Stelara.&n...

Bio & Pharma Celltrion releases Remsima SC in Denmark

South Korea's Celltrion Inc. announced on Thursday that it released its autoimmune disease treatment Remsima SC (infliximab) in Denmark. Remsima SC ...

Future mobility Hyundai, Toray to team up to develop mobility materials

Hyundai Motor Group said on Thursday it has signed a strategic partnership agreement with Japan's Toray Industries Inc. to jointly develop carbon fi...

Bio & Pharma Genesystem enters Indian tuberculosis treatment market

Genesystem, a South Korean biotech company said on Tuesday that it will export 20 on-site tuberculosis (TB) diagnostic devices and 6,000 TB test kit...

Bio & Pharma Reversing age possible in a decade: Harvard Prof. David Sinclair

Humans will be able to control biological age and reverse their age in 10 years with advancements in medical science and live up to around 120, abou...

Bio & Pharma Vivid Health gets seed round from Kakao Ventures

Vivid Health, a South Korean startup that operates an obesity treatment management platform announced on Wednesday that it got a seed round investme...

Bio & Pharma Celltrion ships initial supply of Zymfentra to US

South Korea's Celltrion Inc. announced on Wednesday that it shipped the first supply of its subcutaneous injection type of the autoimmune disease tr...

Bio & Pharma Samsung Bioepis to supply Hadlima to US government

South Korea’s Samsung Bioepis and the US-based Organon, the local partner company of Samsung group's biopharmaceutical research and developmen...